ESR2 and colorectal carcinoma: Studies in ApcMin/+ mice and CRC cell lines have demonstrated the protective role of ERβ in CRC development, where ERβ deletion leads to increased colonic adenomas, while ERβ-specific agonists exhibit tumor-suppressive effects [30].